==== Front Adv Biomed ResAdv Biomed ResABRAdvanced Biomedical Research2277-9175Medknow Publications & Media Pvt Ltd India ABR-7-11510.4103/abr.abr_81_18Letter to EditorResponse to “Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial” Patil Anant D From the Department of Pharmacology, Dr. DY Patil Medical College, Navi Mumbai, Maharashtra, IndiaAddress for correspondence: Dr. Anant D Patil, Department of Pharmacology, Dr. DY Patil Medical College, Navi Mumbai - 400 706, Maharashtra, India. E-mail: anantd1patil@gmail.com2018 20 7 2018 7 115Copyright: © 2018 Advanced Biomedical Research2018This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial ==== Body Sir, I read with a great interest the article titled, “Levofloxacin-containing versus clarithromycin-containing therapy for Helicobacter pylori eradication: A prospective randomized controlled clinical trial”[1] authored by Sebghatollahi et al. I would like to compliment the authors for conducting a study on a widely prevalent disease with a very good design. The results of this study provide many insights about the management of H. pylori infection in the current scenario. In the inclusion criteria, the authors have mentioned that patients with peptic ulcer disease were included; however, it seems many patients in the study did not have gastric/duodenal ulcer. It looks like patients with H. pylori infection with peptic ulcer disease or dyspepsia both were included. Although there was no significant difference in two groups, many findings including numerically higher eradication rate, lower incidence of self-reported adverse events, and severe intolerance are in favor of the pantoprazole, bismuth subcitrate, amoxicillin and clarithromycin (PBAC), i.e., clarithromycin-containing group. In the absence of significant difference between the two groups, comparative data on compliance of two regimens may be useful for a clinical decision of selecting one regimen over the other. If medicines are not provided in the kit, there are chances of lesser compliance in the pantoprazole, bismuth subcitrate, amoxicillin 1 g, tinidazole for 7 days, followed by levofloxacin for next 7 days (PBATL) group, because patients need to change from tinidazole to levofloxacin after a week unlike in the PBAC group where therapy was same for 14 days. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest. ==== Refs Reference 1 Sebghatollahi V Soheilipour M Khodadoostan M Shavakhi A Shavakhi A Levofloxacin-containing versus clarithromycin-containing therapy for Helicobacter pylori eradication: A prospective randomized controlled clinical trial Adv Biomed Res 2018 7 55 29657940